Objective: Published screening mammography performance measures vary across countries. An international study was undertaken to assess the comparability of two performance measures: the recall rate and positive predictive value (PPV). These measures were selected because they do not require identification of all cancers in the screening population, which is not always possible.
INTRODUCTION
E arly detection with mammography has the potential to reduce breast cancer mortality rates. [1] [2] [3] [4] An important indicator of mammography performance is sensitivity, the measure of a test's ability to detect cancer. Measuring sensitivity can be difficult, however, due to incomplete follow-up for cancer determination. Because complete follow up is not always possible or may take a long time to obtain, surrogate performance measures have been advocated. One such measure is the recall rate, defined as the percentage of screening mammograms that require the patient to have further imaging work-up in order to arrive at a recommendation for that patient. The European Guidelines recommend an acceptable recall rate of <7% and a desirable rate of <5% for initial mammography and an acceptable rate of <5% and a desirable rate of <3% for subsequent mammography. 5, 6 The American College of Radiology recommends an overall recall rate of <10%. 7, 8 It is likely that there is an optimal recall rate, although few studies have investigated this issue. 9 A recall rate that is too high means that screening program resources are probably used inefficiently and women undergo unnecessary followup procedures. Conversely, a recall rate that is too low has the potential for lower rates of detecting incident breast cancers.
Variation in recall rates is evident within the US, across Europe and elsewhere. [10] [11] [12] Published rates range from 1.4% for the initial and 0.7% for subsequent mammograms in the Netherlands 13 to 13.8% for the initial and 8.6% for subsequent screening mammograms in Canada. 14 Variation in mammography performance measures that may be related to recall rates also exists across countries. For example, when comparing biopsy yield in the US to other countries, the US has higher rates, 11, 12 and lower cancer yield. This may result from different recall rates, different biopsy rates from positive screens, or possibly different characteristics of the women being screened.
Reasons for variation in recall rates are not well understood. They may reflect differences in screening program organization 15 or in definitions of recall, as well as in how recall data are collected. Other factors that may influence the recall rate include the age of the women being screened, whether symptoms are present at screening or the woman has a history of breast biopsies, or whether the woman has a family history of early breast cancer in first-degree relatives. Breast density and hormone replacement therapy use may also influence the recall rate. Furthermore, factors related to the screening program such as whether one-or two-view mammography is used, 16, 17 whether mammograms are double-read, 17-21 the method for reaching consensus when multiple interpretations are discrepant, the volume of mammograms read by the radiologist, and whether clinical breast examination 22 results are known to the radiologist at the time of mammogram interpretation are possible influences. Finally, factors related to the health care delivery system, such as the extent to which screening is provided within the context of an organized program and the mal-practice environment, may affect recall rates. Few studies have examined the potential influence of these factors.
This paper summarizes a project undertaken by the International Breast Cancer Screening Network (IBSN) to explore possible explanations for the variance in recall rates and to evaluate the extent to which recall rates can be compared across countries. The IBSN is an international consortium sponsored by the US National Cancer Institute for the purpose of fostering cross-national efforts to evaluate the quality and effectiveness of screening mammography. 23 The international collaborative project described in this report also examines whether it is possible to compare screening mammography performance measures that are related to the recall rate, such as positive predictive value (PPV) or cancer detection rates that require linking to population cancer data.
METHODS
Following the biennial meeting of the IBSN in 1997, a 13member working group on mammography performance evaluation was formed. This group designed and implemented a three-phase project between 1997 and 2002. Phase I entailed distributing an assessment form among IBSN country representatives to obtain descriptive data on how screening is performed and what specific data related to recall are collected. In Phase II, data for calculation of recall rates and positive predictive values (PPV) of the screening mammogram were collected. In Phase III more targeted and strata-specific data for calculation of recall rates, PPV and cancer detection rates were collected.
Study Group
The 25 member countries of the IBSN were invited to participate. These countries have variations in how screening is delivered and the size of the population that they screen. This information has been previously published. 10, 11, [24] [25] [26] Phase I
An assessment form that requested information specific to how mammograms were read and interpreted was distributed to IBSN country representatives by e-mail in autumn 1999. The following specific data on factors that may affect screening outcomes were also requested: number of facilities in the program, number of radiologists, whether mammograms are double-read and how differing assessments are resolved, use of one-or two-view mammography, use of clinical breast examination in conjunction with screening mammography, categories used for recording breast density, and whether program data include women with a history of breast cancer, breast biopsy, or surgery. As the US does not have a government-sponsored, organized screening program comparable to those found in many countries with more centralized health care systems, the assessment form was sent to the statistical coordinating center of the National Cancer Institute's Breast Cancer Surveillance Consortium. The consortium is a surveillance research program focusing on community-based screening mammography within six regions across the US. 27 Consortium sites are located in counties that contain slightly more than 5% of the US population. Consortium data closely reflect the US population 28 and are comparable to data collected by the varied international screening programs.
Phase II
In order to evaluate whether collecting similarly structured data was possible, in spring 2000 we distributed a set of tables that requested the number of screening mammograms delivered over any 12 month period between 1996-1999, the number of women recalled for further workup, the number of breast cancers identified in those recalled, and the total number of breast cancers detected in those screened to IBSN country representatives by e-mail. We requested these data with and without the inclusion of technical recalls, defined as repeat screening mammograms for technical reasons only (poor positioning or poor processing). We also requested the following data stratified by age group: whether women had a family history of breast cancer, were current hormone replacement therapy (HRT) users, had clinical breast examination (CBE) performed before or at the time of the mammography or had symptoms at screening. In addition, we requested data on the recording of breast density, the number of screening views used, the time since previous mammogram, and whether the mammograms were double read. We learned from Phase II that (other than for age, number of views and double reading) there was wide variation in data availability and collection procedures across countries, which made obtaining comparable data very difficult.
Phase III
As a result of the Phase II data collection, we distributed a reduced table for data stratified by three age groups (50-54, 55-59 and 60-64 years), family history of breast cancer, and current use of HRT to IBSN country representatives by e-mail in summer 2001. We also asked for data based on number of views and double reading for specific periods of time since previous mammogram (initial screening, 9-17, 18-29, 30-42 and >42 months).
We had learned from Phase II that countries could consistently identify cancers following positive mammograms, but not all were able to identify interval breast cancers (i.e. those that follow a negative mammogram). We therefore restricted our cancer outcomes to cancer detection rates and PPV (Table 1) . PPV was calculated for the screening examination alone without further assessment included.
Evaluating data by time since previous mammogram was essential to our analysis, as screening programs were in different stages of implementation and had varying proportions of initial mammography examinations. Recall and PPV are known to differ by screening interval and whether a screening mammogram is the initial or a subsequent study. 9, 13, 14, 29 
Definitions
Definitions are shown in Table 2 .
᭜ Recall was counted if a screening mammography resulted in a recommendation for further imaging or surgical/ clinical visit because of an abnormality seen on the screening exam; ᭜ Cancers were counted as related to the mammography examination if they occurred within 365 days of the screening mammography date, as a result of the diagnostic assessment following the recall recommendation. If a woman had a second screen prior to the 365 days, the follow up period was truncated at the next screening date; ᭜ Family history of breast cancer was positive if a first-degree relative (i.e., mother, sister, or daughter) had breast cancer.
Analysis
Recall rates, PPV and cancer detection rates were computed for initial and subsequent screening mammograms by age group and time since last mammogram. We present recall rates by initial and subsequent mammograms for the 18-29 month time period and show the relationship between increasing recall rates, PPV and cancer detection. Further analyses were beyond the scope of this effort. We chose to include data from all countries that participated in Phase III, even when the numbers of mammograms were small. We have displayed the confidence intervals to demonstrate the greater uncertainty of estimates from these programs.
RESULTS

Phase I
Twenty-two countries responded to the Phase I survey ( Table 2 ). These countries differ in the way in which they deliver screening mammography, and coverage of the population varies from the total population to a limited number of districts or counties. For example: Canada, Denmark, Finland, France, Israel, Italy, Luxembourg, the Netherlands, Norway, Spain, Sweden, Uruguay and England have organized screening programs paid for by the government. At the time of the data collection, screening mammography in Japan was conducted within a clinical trial, 30, 31 Belgium and Hungary did not have government sponsored screening programs, and the US did not have a universal screening program. In France the organized screening program only covered 45% of the target population, with a 43% participation rate, and opportunistic screening was widely prevalent. The organization of many of these screening programs has been previously described. 15, 24 There were some limiting factors specific to certain countries in regard to data collection. The data from Switzerland were from the last two years of a pilot phase of screening and the number of mammograms was small. 25 Greece had limited data and only the overall recall rates are reported for this country. In Sweden, a national centralized data system did not exist, and data had to be pooled from the individual counties covered by the national program. In France the national organized screening database collects aggregate data from each district on a yearly base. Because the US does not have a centralized program, data were pooled from six distinct Registries that use common data structures. 27 As can be seen in Table 2 , there is no single category for which every country could report data in the same way. All the countries in Table 2 were able to report data for the age group 50-69 years, though not all could stratify by five-year age groups. During the study period, Japan, Belgium and France used one-view mammography for initial mammograms; the other countries reported using two-view. There was greater variation across countries in use of one-versus two-view for subsequent mammography (data not shown).
Information from CBE performed prior to or at the time of mammography may affect the radiologist's interpretation or recommendation. 32 Five of the countries always knew the results of a CBE, seven never had this information, and the others had this information sometimes or in a subset of facilities in the program. Double reading was widely used in many European countries, but was less frequent in the US, England, Israel, Belgium and Spain. Among those countries or programs that used double reading, there was variation in how the second interpretation was handled in making the recall decision, though most employed some form of consensus. Half of the countries reported doing a second read blinded to the results of the first and half were not read in a blinded fashion. There was also disparity in whether readers of mammography were dedicated to mammography alone. In two countries, full-time mammographers read all films. In the other countries the percentage interpreted by part-time readers varied from 0%-100%.
Breast density was only recorded by nine of the 22 responding countries. Among these nine, there was no predominant way that density was classified; two used the Wolfe classification, 33 one used four gradations of fatty to dense, three used three gradations of fatty to dense, and three used different criteria to classify mammograms as dense or not dense. One country only records breast density for diagnostic mammograms.
Information on whether women appeared for screening with a history of a breast biopsy or surgery was available from 15 countries, and information on whether the woman had a history of breast cancer was available in 12. Several assumed that women did not have a history of breast cancer because these women were specifically not invited to screening.
Phases II and III
Fourteen countries responded to the data request for Phases II and III. For Phase III, data on initial mammograms were reported separately and were accepted for any one, two or three years during the period 1997-1999. For subsequent mammograms, data were stratified by time since previous mammogram. Twelve of the fourteen countries were able to report data for the initial screening mammogram (Table 1) . For subsequent mammograms, the time period with the most data reported was for the repeat mammogram in 18-29 months; 10 countries provided data for this time period. The number of mammograms reported varied from 1769 (Switzerland) to 285,322 (England). The mammography data from the Netherlands, France and England were entirely from initial screening; the mammography data from Norway were entirely from the subsequent 18-29 month time period. Among the remaining countries, the proportion of initial mammograms varied from 1.8% (Spain) to 58.3% (Canada).
All the measures in Table 3 are given in order of increasing recall rates for the initial mammograms. The order for subsequent mammograms was similar to that of the initial mammograms. Recall rates for initial screening mammography ranged from 1.4% in the Netherlands to 15.1% in the US. In all countries with data on initial and subsequent mammography, the recall rates from subsequent mammograms were lower than rates for initial mammograms. Recall rates in the subsequent (18-29 months) mammograms ranged from 1.6% in Portugal to 9% in the US There was no consistent relationship of initial to subsequent PPV. As expected, however, there was a pattern of decreasing PPV with increasing recall rate, for both initial and subsequent mammograms. PPV for initial mammograms was as high as 37.5% in the Netherlands (recall rate 1.4%) and as low as 5% in the US (recall rate 15.1%). Luxembourg had the second highest recall rate for initial mammograms (12.2%) and a recall rate in the middle of the range for subsequent mammograms (4.8%).
Cancer detection rates showed less variation than did the recall and PPV rates, ranging from 3.7-10.6 per 1000 for initial and 1.7-5.4 per 1000 for subsequent mammograms (Table 3 ). Cancer detection rates did not closely follow the pattern of the recall rates. We examined recall rates, PPV and cancer detection rates by three age groups (50-54, 55-59 and 60-64 years) for initial and subsequent mammograms (Figures 1-3) . Though the absolute rates differ across the countries, the patterns were similar for recall rates by age in all countries: recall rates of 7.8 or higher for initial mammograms and 3.8 or higher for subsequent mammograms, and decreasing recall rates with increasing age. With few exceptions (Switzerland in the subsequent mammograms and Spain in the initial mammo-grams), PPV increased with age. For cancer detection rates, the patterns were not as clear. For most countries, the cancer detection rates for initial mammograms were highest in the oldest age group. As can be seen in Figure 4 , cancer detection rates do not increase steadily as the recall rate increases. This was true for the initial and subsequent time periods. The rise in cancer detection with increasing recall rate may be greater at the lower end of the scale. We caution against overinterpretation of these results. 
DISCUSSION
Comparison of recall rates among screening mammography programs internationally was undertaken by a working group of the IBSN to determine whether there could be meaningful evaluation performed on comparable data. Published data on screening mammography performance, as practiced during the period 1997-1999, varied by country. The question is whether the results are truly different or whether the data are not comparable. Our results point clearly to differences in both the organization of screening mammography practice and in data collection that may result in non-comparable screening performance estimates across countries. At the same time, we documented similar patterns across countries in the association of recall rates and PPV with age. We found variation between countries in methods of screening and interpretation that may affect recall rates. Differences existed in the use of one-versus two-view mammography, double reading, and the method for arriving at a resolution when double reading led to different assessments. Independent double reading contributes to higher recall rates, 21, 34 while consensus double reading is likely to lower them. 19 With this limited number of programs (12 for calculation of initial recall rates and 10 for subsequent recall rates), we were unable to conduct statistical modeling to test for associations of these factors with recall rates. The three countries using single view mammography reported relatively higher recall rates for initial (8%, 11% and 12%) and subsequent mammograms (6% and 7%, with one not reporting subsequent rates).
In addition to practice differences, and perhaps more important, there were differences in data collection that may have affected comparability of recall rates. It is widely known that breast density affects mammography performance, 35 yet nine programs did not record breast density, and of those that did, there was great variation in how density was classified. Carney et al. have shown that breast density is related to age; both have an effect on performance characteristics, although the effect of density was greater than that of age. 35 As most would agree that density should be controlled for in any comparison of recall, PPV or other performance measures, this raises potential problems for international comparative work. The presence of symptoms at screening is another important modifier of performance estimates, as women presenting with symptoms may have higher recall and PPV rates. 9, 36 Only five of the programs recorded whether a woman had symptoms at the time of mammography.
Wide variation was observed in the recall rate (range 1.4-15.1%), and thus also in PPV rates (range 5-37.5%), as recall directly influences PPV. The highest recall rates were in the US and the lowest in the Netherlands (15% and 1.4% respectively for initial screening). As may be expected, the PPV results were the opposite, with the highest in the Netherlands and lowest in the US (37.5% and 5% respectively). These are as expected as the greater the number of recalls, the greater the probability of false positive results. These differences in recall rates may be affected by factors that we could not measure, including prevalence of cancer in the screening population, radiologist training, quality of mammography, and in some instances, malpractice concerns.
Cancer detection rates did not demonstrate the same relationships as did recall and PPV. Overall, the cancer detection rates per 1000 ranged from 3.9-10.6. For initial mammograms, the Netherlands, with a very low recall rate and very high PPV (1.4%, 37.5%), had a low cancer detection rate of 5.3/1000. The US, with a recall rate 10-fold higher and low PPV (15%, 5%), had a cancer detection rate of 7.5/1000, only modestly higher than that of the Netherlands. As noted by Elmore et al. in their literature review, 11 increases in recall rate were not directly associated with improved cancer detection rates. Yankaskas et al. have reported improvements in sensitivity with rising recall rates in the lower range (up to about 8%) 9 and our data suggest that cancer detection rates may rise with increases in the lower range of recall rates. There does not appear to be a direct relationship of recall to cancer incidence either. Whether using crude cancer incidence or age standardized incidence, cancer incidence rates are similar for the US (130/100,000 crude, 90/100,000 standardized) and the Netherlands (136/100,000 and 92/100,000), though they are at opposite ends of the scale for recall rates (US 15.1%, the Netherlands 1.4%). 11 The number of cancers may be too small to draw any conclusion. Further evaluation with more years of data would be useful.
In spite of these differences, some consistent patterns in recall rate and PPV were evident. With a few exceptions, recall rates and PPV were higher in initial than in subsequent mammograms. Recall decreased with increasing age, for first and initial screening mammography. Conversely, cancer rates increased with age and decreased between first and subsequent screens.
Where do we go from here? Similar patterns in association of performance measures make it possible to design studies that look at international trends rather than absolute estimates. However, the countries participating in this study agree that it would be useful to have more specific answers to questions about variations in assessment rates from screening mammography and whether program or data differences explain the variation. With such information available, multivariate modeling to explain differences might be possible. As cancer detection rates across countries are relatively similar, it seems possible that a reasonable international standard for recall rate could be established. One study in the US found that a recall rate of around 5% was associated with the best trade off between sensitivity and PPV. 9 These findings, however, cannot be easily transferred to programs in other countries because of the issues raised in this work. If data on breast density, presence of symptoms, and HRT use at the time of screening were recorded in a consistent standardized format, we would improve our ability to adjust for population differences and make more valid comparisons of recall rates across countries, as well as adjust for underlying cancer incidence from national rates.
For the future, agreement on standards for data definitions and collection, even for a core set of parameters, would be a good start. A discussion of the effect of different definitions has been published 37 and standardization has been achieved among the six screening mammography registries that make up the US BCSC. 27 This has enabled comparison of mammography results as well as analyses from pooled data. 35, [38] [39] [40] If what is learned in one country is to be generalized to another, some standardization will be necessary.
In conclusion, this study of the feasibility of comparing recall rates among international screening programs demonstrated variation in the practice of screening mammography and in data collection for two key measures of mammography performance. We found that recall had a similar association with age across the programs, in both first and subsequent mammography. There were large variations in how screening data were recorded and the coding systems for these data that made it difficult to compare recall rates, PPV and cancer detection rates across countries. Nevertheless, consistent patterns of decreasing PPV with increasing recall were observed across countries, as was the lack of a pattern for cancer detection rate with rising recall rate. Development of a more standardized approach to data collection and definitions would allow more meaningful comparison across countries, with the potential to optimize screening performance. At present, comparisons of screening performance among countries should be undertaken with caution due to data collection differences that may affect data comparability.
